Coronavirus (COVID-19) mRNA vaccine BNT162b2 Pfizer/BioNTech: national protocol

Protocol guidance for the COVID-19 mRNA Vaccine BNT162b2 Pfizer/BioNTech.

This document is part of a collection

5. Clinical condition or situation to which this Protocol applies

COVID-19 mRNA Vaccine BNT162b2 Pfizer/BioNTech is indicated for active immunisation against COVID-19 disease caused by SARS-CoV-2 virus in accordance with Scottish Government COVID-19 immunisation programme and recommendations given in Chapter 14a of the Immunisation Against Infectious Disease: the 'Green Book' COVID-19: the green book, chapter 14a and Scottish Government CMO letters relating to COVID-19 vaccination.



Back to top